Massanella, Marta
Gianella, Sara
Schrier, Rachel
Dan, Jennifer M.
Pérez-Santiago, Josué
Oliveira, Michelli F.
Richman, Douglas D.
Little, Susan J.
Benson, Constance A.
Daar, Eric S.
Dube, Michael P.
Haubrich, Richard H.
Smith, Davey M.
Morris, Sheldon R.
Article History
Received: 17 March 2015
Accepted: 14 July 2015
First Online: 24 August 2015
Competing interests
: MM, SG, RS, JD, JPS, MFO and CB do not have any commercial or other associations that might pose a conflict of interest. For the rest of authors, there is potential Competing Interest. DDR has served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Merck & Co, Monogram Biosciences and Chimerix. SJL has received grant support from Gilead Sciences. ESD has received grant support from Bristol Myers Squibb, Gilead and ViiV and has acted as a consultant for Abbvie, Bristol Myers Squibb, Gilead, Merck, Teva and ViiV. MPD has received grant support from Merck, Gilead, Serono and ViiV and has served as a consultant to Serono. RHH reports having received honoraria or consultant fees from BMS, Gilead Sciences and Janssen and research support (to UCSD) from Abbott, GlaxoSmithKline, Pfizer and Merck. DMS has received grant support from ViiV Pharmaceuticals and consultant fees from Gen-Probe and Testing Talent Services. SRM has served on advisory boards for and received grant support from Gilead Sciences.